Abrégé

The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.

Classes IPC  ?

• A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Abrégé

The disclosure provides methods for administering buprenorphine in a healthcare setting by an administering practitioner to a patient in need thereof. The methods of the disclosure comprise obtaining buprenorphine from a REMS-certified pharmacy or a REMS-certified healthcare setting. Said administering does not require the administering practitioner to be REMS-certified.

Classes IPC  ?

• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 31/33 - Composés hétérocycliques

Abrégé

The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.

Classes IPC  ?

• A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Abrégé

Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61M 15/00 - Inhalateurs
• A61M 15/06 - Appareils à inhalation en forme de cigares, de cigarettes ou de pipes
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool

Produits et services

(1) Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment (1) Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports (2) Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Produits et services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Produits et services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Abrégé

The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Classes IPC  ?

• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles

Produits et services

Pharmaceutical preparations and substances in this class. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of information and advice in the field of opioid dependence; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

Classes IPC  ?

• A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
• A61M 5/178 - Seringues
• A61M 5/31 - Seringues Parties constitutives

Abrégé

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Classes IPC  ?

• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères

Produits et services

Pharmaceutical preparations and substances in this class. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of information and advice in the field of opioid dependence; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid overdose, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose symptoms.

Classes IPC  ?

• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Produits et services

Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Produits et services

Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Produits et services

Provision of health care advice; providing information relating to opioid dependence

Produits et services

(1) Printed matter, namely, pamphlets, flyers, and brochures in the field of opioid and other substance use addiction, dependence, prevention, and treatment. (1) Healthcare services, namely, addiction treatment services, providing emergency health information by telephone, counselling regarding the choice of medication, drug usage and information on side effects, and drug addiction counselling services; providing medical information in the field of treatment of opioid addiction; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice in the field opioid dependence, and treatment of and recovery from opioid dependence; provision of pharmaceutical information and advice for medical purposes.

Produits et services

Printed matter, namely, information cards, leaflets and pamplets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Produits et services

(1) Printed matter, namely, pamphlets, flyers, and brochures in the field of opioid and other substance use addiction, dependence, prevention, and treatment. (1) Healthcare services, namely, addiction treatment services, providing emergency health information by telephone, counselling regarding the choice of medication, drug usage and information on side effects, and drug addiction counselling services; providing medical information in the field of treatment of opioid addiction; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice in the field opioid dependence, and treatment of and recovery from opioid dependence; provision of pharmaceutical information and advice for medical purposes.

Produits et services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Abrégé

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Classes IPC  ?

• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The disclosure provides methods for treating, preventing, and reducing the incidence of opioid-induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Produits et services

(1) Pharmaceutical preparations; medicines for human and veterinary purposes; pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain (2) Medical and veterinary apparatus; Medical apparatus for diagnosing or treating substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, and for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain (1) Medical services; health care; medical clinic services; medical research services; health counselling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain

Produits et services

(1) Healthcare services, namely, addiction treatment services, providing emergency health information by telephone, counselling regarding the choice of medication, drug usage and information on side effects, and drug addiction counselling services; providing medical information in the field of treatment of opioid addiction; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of pharmaceutical information and advice for medical purposes.

Produits et services

(1) Healthcare services, namely, addiction treatment services, providing emergency health information by telephone, counselling regarding the choice of medication, drug usage and information on side effects, and drug addiction counselling services; providing medical information in the field of treatment of opioid addiction; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of pharmaceutical information and advice for medical purposes.

Abrégé

Drug products adapted for nasal delivery comprising naltrexone, alone or in combination with excipients, are provided. Pre-primed devices for intranasal administration of the drug products are also provided. In addition, methods for treating and preventing a variety of opioid receptor-mediated diseases, disorders, addictions, symptoms, reward-based behaviors, and conditions with the drugs products are provided

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
• A61K 9/08 - Solutions
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine

Abrégé

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).

Classes IPC  ?

• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Provided are formulations and methods for treating, reversing, or reducing acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or symptom(s) thereof.

Classes IPC  ?

• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
• A61K 9/107 - Émulsions
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 39/02 - Antidotes

Produits et services

Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Produits et services

Providing an interactive web site featuring technology that enables users to search, locate and access health care and medical service providers; providing an interactive web site featuring technology that enables users to search, locate and access injection administration service providers Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes; provision of health care information and advice relating to administration of pharmaceutical injectables

Produits et services

Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Abrégé

The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Abrégé

Disclosed herein are formulations and methods for reversing cannabinoid overdose or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose or symptom(s).

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine

Abrégé

The disclosure provides methods for treating, preventing, and reducing the incidence of opioid- induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61P 11/06 - Antiasthmatiques
• A61P 11/08 - Bronchodilatateurs
• C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone

Abrégé

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Classes IPC  ?

• G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• G06F 16/11 - Administration des systèmes de fichiers, p. ex. détails de l’archivage ou d’instantanés
• G06F 9/48 - Lancement de programmes Commutation de programmes, p. ex. par interruption
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés

Abrégé

min ratio of less than 200 and a lag time less than 0.2.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
• A61K 9/16 - AgglomérésGranulésMicrobilles

Abrégé

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/38 - CelluloseSes dérivés

Abrégé

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Classes IPC  ?

• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères

Abrégé

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

Classes IPC  ?

• A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
• A61M 5/178 - Seringues
• A61M 5/31 - Seringues Parties constitutives

Abrégé

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

Classes IPC  ?

• A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
• A61M 5/178 - Seringues
• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles

Abrégé

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07D 493/08 - Systèmes pontés

Abrégé

The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Classes IPC  ?

• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• C07D 487/04 - Systèmes condensés en ortho
• C07D 498/04 - Systèmes condensés en ortho
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
• A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons

Produits et services

Pharmaceutical preparations for the treatment of mental health diseases and disorders; Medicines for human and veterinary purposes, namely, medicines for the treatment of mental health diseases and disorders

Abrégé

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones

Abrégé

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Abrégé

min ratio of less than 200 and a lag time less than 0.2.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
• A61K 9/16 - AgglomérésGranulésMicrobilles

Abrégé

3 receptors, such as treating substance abuse or psychiatric diseases.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles

Abrégé

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 493/08 - Systèmes pontés
• C07D 471/04 - Systèmes condensés en ortho
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Abrégé

3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Classes IPC  ?

• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
• C07D 487/04 - Systèmes condensés en ortho
• C07D 498/04 - Systèmes condensés en ortho
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
• A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons

Abrégé

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
• G06F 16/11 - Administration des systèmes de fichiers, p. ex. détails de l’archivage ou d’instantanés
• G06F 9/48 - Lancement de programmes Commutation de programmes, p. ex. par interruption

Abrégé

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Classes IPC  ?

• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/51 - Thiamines, p. ex. vitamine B1
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
• G06F 9/48 - Lancement de programmes Commutation de programmes, p. ex. par interruption
• G06F 17/30 - Recherche documentaire; Structures de bases de données à cet effet

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 493/08 - Systèmes pontés
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles

Abrégé

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones

Produits et services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Produits et services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Produits et services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Produits et services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Produits et services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports Provision of medical information and advice via a website in the field of opioid dependence and its treatment; Provision of medical information and advice in the field of opioid dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Produits et services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports Provision of medical information and advice via a website in the field of opioid dependence and its treatment; Provision of medical information and advice in the field of opioid dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Produits et services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Abrégé

The disclosure provides orally administrable capsules comprising abuse-resistant, pharmaceutical formulations which comprise abuse-susceptible active agents such as opioids. The formulations provide abuse resistance by having a sufficiently high viscosity that substantially prevents the formulation and opioid therein, from being drawn into a syringe, at room temperature or higher, either alone or when mixed with water or other liquids.

Classes IPC  ?

• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

Classes IPC  ?

• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux

Abrégé

min ratio less than 200 and lag time less than 0.2.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

Classes IPC  ?

• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/02 - Composés inorganiques
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux

Abrégé

The disclosure provides methods for the detection and quantification of drugs and drug metabolites in biological samples, such as naloxone, buprenorphine, and norbuprenorphine.

Classes IPC  ?

• G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques

Produits et services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Produits et services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Produits et services

Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice; provision of pharmaceutical information and advice

Produits et services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely, drug rehabilitation counselling services; provision of health care information and advice, namely, providing information to patients in the field of administering medications, providing medical and scientific research information in the field of pharmaceuticals and clinical trials, and pharmacy advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of comorbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of comorbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine D3 receptors, such as treating substance abuse or psychiatric diseases.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

Abrégé

The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Abrégé

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones

Abrégé

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

Classes IPC  ?

• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61K 47/02 - Composés inorganiques
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez

Produits et services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely drug addiction and rehabilitation counselling services; provision of health care information and advice in the field of drug addiction and rehabilitation; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely drug addiction and rehabilitation counselling services; provision of health care information and advice in the field of drug addiction and rehabilitation; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abrégé

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

Classes IPC  ?

• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 9/08 - Solutions
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez

Abrégé

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07D 498/04 - Systèmes condensés en ortho
• A61K 31/5383 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counselling, namely, substance abuse and drug rehabilitation counselling services; provision of health care information and advice in the field of pharmaceuticals, health and wellness, behavioral health, disability management, and disease management; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system diseases and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Produits et services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions

Produits et services

Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans